Genmab Feed

2026-04-01 21:19:27 Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

2026-04-01 09:24:51 Major Shareholder Announcement 1758,50 DKK | +2,66% | 162 MDKK

2026-03-30 18:00:10 Major Shareholder Announcement 1713,00 DKK | +1,45% | 193 MDKK

2026-03-19 19:21:43 Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab 1637,00 DKK | -0,49% | 405 MDKK

2026-03-19 15:06:02 Passing of Genmab A/S’ Annual General Meeting 1645,00 DKK | -2,08% | 259 MDKK

2026-03-16 15:09:37 Completion of Share Buy-back Program 1714,50 DKK | +0,70% | 187 MDKK

2026-03-09 15:01:23 Transactions in Connection with Share Buy-back Program 1725,00 DKK | -0,20% | 239 MDKK

2026-03-02 22:53:34 Correction to Company Announcement No. 13 of March 2, 2026 1766,00 DKK | -5,18% | 372 MDKK

2026-03-02 20:58:26 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1766,00 DKK | -5,18% | 372 MDKK

2026-03-02 15:04:17 Transactions in Connection with Share Buy-back Program 1862,50 DKK | +0,76% | 297 MDKK

2026-02-27 21:23:46 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

2026-02-27 21:21:57 Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

2026-02-25 16:27:25 Genmab to Participate in Upcoming Investor Conferences 1833,00 DKK | -1,00% | 254 MDKK

2026-02-24 21:20:58 Capital Increase in Genmab as a Result of Employee Warrant Exercise 1833,00 DKK | -1,00% | 254 MDKK

2026-02-23 15:33:32 Transactions in Connection with Share Buy-back Program 1832,50 DKK | -1,13% | 320 MDKK

2026-02-20 16:05:35 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1853,50 DKK | +3,46% | 319 MDKK

2026-02-18 15:09:51 Notice to Convene the Annual General Meeting of Genmab A/S 1825,00 DKK | -6,58% | 567 MDKK

2026-02-17 21:14:18 Genmab Announces Initiation of Share Buy-Back Program 1825,00 DKK | -6,58% | 567 MDKK

2026-02-17 17:23:40 Genmab Files Annual Report with the U.S. Securities and Exchange Commission 1825,00 DKK | -6,58% | 567 MDKK

2026-02-17 17:01:38 Genmab Publishes 2025 Annual Report 1825,00 DKK | -6,58% | 567 MDKK

2026-01-29 18:49:01 Grant of Restricted Stock Units and Warrants to Employees in Genmab 2022,00 DKK | -2,18% | 290 MDKK

2026-01-21 12:23:32 Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 2088,00 DKK | +4,50% | 320 MDKK

2026-01-16 19:30:00 Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2026-01-07 15:00:00 Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence 2166,00 DKK | +2,36% | 273 MDKK

2026-01-05 13:58:01 Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference 2010,00 DKK | +0,15% | 234 MDKK

2025-12-29 14:10:51 Genmab Portfolio Prioritization Update 2080,00 DKK | -2,03% | 193 MDKK

2025-12-12 07:35:42 Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period 2015,00 DKK | -1,52% | 190 MDKK

2025-12-11 08:00:00 Genmab to Hold 2025 R&D Update and ASH Data Review Meeting 2046,00 DKK | +2,74% | 165 MDKK

2025-12-08 22:30:00 Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) 2010,00 DKK | -2,24% | 255 MDKK

2025-12-07 13:50:00 Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

2025-12-06 15:30:00 Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

2025-12-03 21:03:25 Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes 2062,00 DKK | +1,93% | 197 MDKK

2025-12-01 22:24:46 Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons 2034,00 DKK | -0,44% | 206 MDKK

2025-11-24 13:00:00 Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami 2006,00 DKK | +1,93% | 473 MDKK

2025-11-20 21:02:31 Grant of Restricted Stock Units and Warrants to Employees in Genmab 1968,00 DKK | +0,56% | 164 MDKK

2025-11-19 18:56:05 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 1957,00 DKK | -1,11% | 191 MDKK

2025-11-18 22:01:23 Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility 1979,00 DKK | +3,29% | 269 MDKK

2025-11-18 20:58:42 Capital Increase in Genmab as a Result of Employee Warrant Exercise 1979,00 DKK | +3,29% | 269 MDKK

2025-11-18 17:30:00 Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma 1979,00 DKK | +3,29% | 269 MDKK

2025-11-10 16:51:38 Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes 1875,50 DKK | +1,52% | 269 MDKK

2025-11-10 13:12:42 Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility 1875,50 DKK | +1,52% | 269 MDKK

2025-11-06 17:02:22 Genmab Announces Financial Results for the Nine Months of 2025 1847,50 DKK | -1,07% | 248 MDKK

2025-11-05 18:58:52 Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London 1867,50 DKK | +1,55% | 290 MDKK

2025-11-03 15:05:00 Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting 1864,50 DKK | +1,44% | 221 MDKK

2025-10-21 14:12:17 Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. 1918,00 DKK | -3,45% | 577 MDKK

2025-10-18 12:00:34 Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

2025-10-14 12:23:16 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 2085,00 DKK | +0,39% | 513 MDKK

2025-09-29 07:08:41 Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model 1832,00 DKK | -0,46% | 626 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Genmab

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden